{"id":16403,"date":"2020-06-22T09:14:12","date_gmt":"2020-06-22T13:14:12","guid":{"rendered":"https:\/\/phrg.ca\/recherche\/etudes-cliniques\/"},"modified":"2020-10-31T12:04:38","modified_gmt":"2020-10-31T16:04:38","slug":"etudes-cliniques","status":"publish","type":"page","link":"https:\/\/phrg.ca\/en\/recherche\/etudes-cliniques\/","title":{"rendered":"Clinical trials"},"content":{"rendered":"<p>[vc_row][vc_column css=&#8221;.vc_custom_1543924365737{padding-right: 25px !important;padding-left: 25px !important;}&#8221;][vc_column_text]Clinical trials constitute the last stage of research, before the marketing of new therapeutic molecules. A rigorous selection process is carried out to choose a promising molecule for the prevention, treatment or diagnosis of a disease, while minimizing the risks of adverse effects.<\/p>\n<p>Potentially therapeutic molecules must be approved by government authorities before being administered to a volunteer.\u00a0Depending on the nature of the study, the new molecule can be administered to a healthy volunteer or to a sick patient who is not responding well to current treatments.<\/p>\n<p>Research carried out within the pulmonary hypertension research group has led to the discovery of several promising molecules.\u00a0Consult your doctor to verify your eligibility for one of our studies in pulmonary hypertension or pulmonary fibrosis.<\/p>\n<p>Clinical trials within the group are divided into two main areas: pulmonary hypertension and fibrosis.[\/vc_column_text][vc_empty_space height=&#8221;30px&#8221;][vc_single_image image=&#8221;16253&#8243; img_size=&#8221;full&#8221;][vc_empty_space height=&#8221;60px&#8221;][\/vc_column][\/vc_row][vc_row][vc_column][vc_tta_tabs style=&#8221;insignia_tab_layout3 title-font&#8221; active_section=&#8221;1&#8243;][vc_tta_section title=&#8221;Pulmonary hypertension&#8221; tab_id=&#8221;pulmonary-hypertension&#8221;][vc_row_inner gap=&#8221;35&#8243;][vc_column_inner][vc_empty_space height=&#8221;30px&#8221;]<div id='ins-heading-69d7b491728a5' class='section-heading ins-heading default default    '  style='margin-top:0; margin-bottom:0'><h3 class='section-heading-title margin-10px-top  default '><\/h3><h6 class='section-heading-subtitle title-font  default '>Ongoing trials<\/h6><\/div><script type=\"text\/javascript\">\n\t\t(function(jQuery) {\n\t\t\t\t\t})(jQuery);\n\t\t\t\t\t\t<\/script>[\/vc_column_inner][\/vc_row_inner][vc_row_inner gap=&#8221;35&#8243;][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text]<\/p>\n<ul>\n<li><strong>\u00c9tude BRD4<\/strong><br \/>\nA Randomized, multicentric\u00a0 phase 2 study of BRDs inhibitor, Apabetalone vs Placebo, in Subjects with Pulmonary Arterial Hypertension (NCT03655704).<\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_empty_space height=&#8221;30px&#8221;][vc_column_text]<\/p>\n<ul>\n<li><strong>\u00c9tude PARP1<\/strong><br \/>\nA Randomized, multicentric\u00a0 phase I\u00a0study of PARP1 inhibitor, Olaparib, in Subjects with Pulmonary Arterial Hypertension (NCT03251872).<\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_empty_space height=&#8221;30px&#8221;][vc_column_text]<\/p>\n<ul>\n<li><strong>The influence of respiratory system compliance on pulmonary artery pressures in obese patients with pulmonary hypertension<br \/>\n<\/strong>Accurate measurements of pulmonary vascular pressures are essential to the appropriate diagnosis, patient&#8217;s characterization and treatment of pulmonary hypertension. Pulmonary artery pressure could be influenced by subject&#8217;s weight and pulmonary function. In this project, we want to compare pressure on pulmonary vascular pressures on 3 groups: subjects with a body mass index between 18.5 to 24.9kg\/m<sup>2<\/sup>, between 25.0 to 29.9 kg\/m<sup>2<\/sup>\u00a0and more than 30.0 kg\/m<sup>2<\/sup>.<\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_empty_space height=&#8221;30px&#8221;][vc_column_text]<\/p>\n<ul>\n<li><strong>Biobank<br \/>\n<\/strong>This project consists to take tissues from a pulmonary transplantation or following a death. These tissues are used to study\u00a0oncoproteins and\u00a0 microRNAs know to be altered in Pulmonary Hypertension.<\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_empty_space height=&#8221;30px&#8221;][vc_column_text]<\/p>\n<ul>\n<li><strong>SELECT<\/strong><br \/>\nThis international, phase 3, randomized, multicenter study evaluates the efficacy and safety of selexipag (a selective IP receptor agonist) versus placebo in patients with chronic postembolic pulmonary hypertension inoperable or persistent after surgery.\u00a0Patients with or without basic treatment are eligible.<\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_empty_space height=&#8221;30px&#8221;][vc_column_text]<\/p>\n<ul>\n<li><strong>ADVANCE<\/strong><br \/>\nThis international, multicenter, randomized phase 3 study evaluates the efficacy and safety of ranelipag (a selective IP receptor agonist) versus placebo in patients already treated for pulmonary arterial hypertension (PAH).<\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text]<\/p>\n<ul>\n<li><strong>New biomarkers predicting severity, prognosis and response to interventions in diverse types of pulmonary hypertension characterized by pulmonary vascular remodeling<br \/>\n<\/strong>Several types of pulmonary hypertension (PH) are characterized by pulmonary vascular remodeling (PVR). The prototype of PVR is pulmonary arterial hypertension (PAH), a disease characterized by progressively increased pulmonary vascular resistance ultimately leading to right ventricular (RV) failure and death. PAH may be idiopathic or associated with various conditions\u00a0and predominantly affects young adults. The prevalence of PAH is estimated at 60 persons per million. Despite newly developed therapies, most patients display persistent exercise intolerance and long-term prognosis remains poor. Limited tools are available to predict long-term outcomes in PAH. More importantly, no biomarkers are predictive of subsequent response to therapy. Referral for life-saving interventions such as lung transplantation is thus uselessly delayed for the significant proportion of patients that are unresponsive to new therapies. PH is also a common complication of cardiovascular diseases, and especially valvular heart diseases (VHD). PH-VHD may be completely reversible upon surgical valve replacement or repair. However, in a subset of patients with long standing PH-VHD, PH is irreversible despite surgery because of progressive PVR. Moreover, postoperative PH-VHD markedly increases the clinical burden of VHD and is a strong predictor of mortality. The complex interaction between the VHD severity, level of PH and other comorbidities, makes the PVR gravity (thus the hemodynamic outcome following surgery) difficult to predict preoperatively<em><strong>.<\/strong><\/em>\u00a0In both conditions, a biomarker directly linked to the PVR process and predicting disease severity and outcomes is thus tragically lacking. The general objective of this proposal is to systematically validate new biomarkers in patients suffering from PAH and PH-VHD.<\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_empty_space height=&#8221;30px&#8221;][vc_column_text]<\/p>\n<ul>\n<li><strong>Skeletal muscle mitochondrial abnormalities and the metabolic syndrome in pulmonary arterial hypertension<br \/>\n<\/strong>Many evidences indicate that exercice limitation in PAH is not simply due to pulmonary hemodynamic impairment, but that other determinants are involved. Interestingly, even in absence of obesity or diabetes, insulin resistance and metabolic syndrome are highly prevalent amongst PAH patients and associated with worse outcomes. Our research group is dedicated to understand the mechanisms of metabolic syndrome development in PAH. Specifically, we aim to compare syndrome development on PAH patients to non PAH patients.<\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner gap=&#8221;35&#8243;][vc_column_inner][vc_empty_space height=&#8221;30px&#8221;][vc_separator color=&#8221;blue&#8221; style=&#8221;shadow&#8221;]<div id='ins-heading-69d7b491728d2' class='section-heading ins-heading default default    '  style='margin-top:0; margin-bottom:0'><h3 class='section-heading-title margin-10px-top  default '><\/h3><h6 class='section-heading-subtitle title-font  default '>Completed trials<\/h6><\/div><script type=\"text\/javascript\">\n\t\t(function(jQuery) {\n\t\t\t\t\t})(jQuery);\n\t\t\t\t\t\t<\/script>[\/vc_column_inner][\/vc_row_inner][vc_row_inner gap=&#8221;35&#8243;][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text]<\/p>\n<ul>\n<li><strong>REPO<br \/>\n<\/strong>A Randomized, monocentric\u00a0study of First-Line Revatio\u00a0in Subjects with Portopulmonary Hypertension.<\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_empty_space height=&#8221;30px&#8221;][vc_column_text]<\/p>\n<ul>\n<li><strong>TRITON<br \/>\n<\/strong>A Randomized, multicentric Study of First-Line Selexipax, Macitentan and Tadalafil Combination Therapy versus Macitentan and Tadalafil combination\u00a0therapy\u00a0of subjects with Pulmonary Arterial Hypertension<\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text]<\/p>\n<ul>\n<li><strong>CATALYST<br \/>\n<\/strong>Monocentric\u00a0Study of Bardoxolon therapy\u00a0in patients\u00a0with pulmonary arterial hypertension (PAH) associated with connective tissue disease.<\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_empty_space height=&#8221;30px&#8221;][vc_column_text]<\/p>\n<ul>\n<li><strong>\u00c9tude Roche FPI-HTP (MA29957)<\/strong><br \/>\nStudy of Sildenafil therapy in patients with idiopathic pulmonary fibrosis with probability of pulmonary hypertension (mPAP\u00a0\u203a 20mmHg or sPAP 34 mmHg +CVP).<\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner gap=&#8221;35&#8243;][vc_column_inner][vc_empty_space height=&#8221;30px&#8221;][\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][vc_tta_section title=&#8221;Fibrose&#8221; tab_id=&#8221;fibrose&#8221;][vc_row_inner gap=&#8221;30&#8243;][vc_column_inner][vc_empty_space height=&#8221;30px&#8221;]<div id='ins-heading-69d7b491728fb' class='section-heading ins-heading default default    '  style='margin-top:0; margin-bottom:0'><h3 class='section-heading-title margin-10px-top  default '><\/h3><h6 class='section-heading-subtitle title-font  default '>Ongoing trials<\/h6><\/div><script type=\"text\/javascript\">\n\t\t(function(jQuery) {\n\t\t\t\t\t})(jQuery);\n\t\t\t\t\t\t<\/script>[\/vc_column_inner][\/vc_row_inner][vc_row_inner gap=&#8221;30&#8243;][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text]<\/p>\n<ul>\n<li><strong>Biobanque<br \/>\n<\/strong>This project consists to take tissues from a pulmonary transplantation, an open biopsy\u00a0or following a death.<\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text]<\/p>\n<ul>\n<li><strong>ISABELLA 2<br \/>\n<\/strong>This international, multicentre, randomized phase 3 study evaluates the efficacy and safety of GLPG 1690 (an autotaxin inhibitor) versus placebo in patients with idiopathic pulmonary fibrosis.<\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner gap=&#8221;30&#8243;][vc_column_inner][vc_empty_space height=&#8221;30px&#8221;][vc_separator color=&#8221;blue&#8221; style=&#8221;shadow&#8221;]<div id='ins-heading-69d7b49172916' class='section-heading ins-heading default default    '  style='margin-top:0; margin-bottom:0'><h3 class='section-heading-title margin-10px-top  default '><\/h3><h6 class='section-heading-subtitle title-font  default '>Completed trials<\/h6><\/div><script type=\"text\/javascript\">\n\t\t(function(jQuery) {\n\t\t\t\t\t})(jQuery);\n\t\t\t\t\t\t<\/script>[\/vc_column_inner][\/vc_row_inner][vc_row_inner gap=&#8221;30&#8243;][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text]<\/p>\n<ul>\n<li><strong>HOPE-IPF<br \/>\n<\/strong>This study consists to perform measurement of\u00a0pulmonary function on diagnostic\u00a0idiopathic pulmonary fibrosis patients\u00a0without\u00a0biopsy. They receive Nintedanib medication.<\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_empty_space height=&#8221;30px&#8221;][vc_column_text]<\/p>\n<ul>\n<li><b>MII unclassifiable\u00a0(study MA39189)<br \/>\n<\/b>This \u00a0is a multicenter, international, randomized phase II trial of Pirferidone in patients with unclassifiable progressive fibrosing interstitial lung disease.<\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text]<\/p>\n<ul>\n<li><strong>Roche FPI-HTP<br \/>\n<\/strong>This \u00a0is a\u00a0randomized study of Sildenafil therapy in\u00a0patients with advanced idiopathic pulmonary fibrosis\u00a0with high probability of pulmonary hypertension (mPAP\u203a 20mmHg on catheterism or sPAP 34mmHg + CVP\u00a0on echo).<\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][\/vc_tta_tabs][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column css=&#8221;.vc_custom_1543924365737{padding-right: 25px !important;padding-left: 25px !important;}&#8221;][vc_column_text]Clinical trials constitute the last stage of research, before the marketing of new therapeutic molecules. A rigorous selection process is carried out to choose a [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":16368,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-16403","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Clinical trials - PHRG<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/phrg.ca\/en\/recherche\/etudes-cliniques\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clinical trials - PHRG\" \/>\n<meta property=\"og:description\" content=\"[vc_row][vc_column css=&#8221;.vc_custom_1543924365737{padding-right: 25px !important;padding-left: 25px !important;}&#8221;][vc_column_text]Clinical trials constitute the last stage of research, before the marketing of new therapeutic molecules. A rigorous selection process is carried out to choose a [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/phrg.ca\/en\/recherche\/etudes-cliniques\/\" \/>\n<meta property=\"og:site_name\" content=\"PHRG\" \/>\n<meta property=\"article:modified_time\" content=\"2020-10-31T16:04:38+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/phrg.ca\\\/en\\\/recherche\\\/etudes-cliniques\\\/\",\"url\":\"https:\\\/\\\/phrg.ca\\\/en\\\/recherche\\\/etudes-cliniques\\\/\",\"name\":\"Clinical trials - PHRG\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/phrg.ca\\\/en\\\/#website\"},\"datePublished\":\"2020-06-22T13:14:12+00:00\",\"dateModified\":\"2020-10-31T16:04:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/phrg.ca\\\/en\\\/recherche\\\/etudes-cliniques\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/phrg.ca\\\/en\\\/recherche\\\/etudes-cliniques\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/phrg.ca\\\/en\\\/recherche\\\/etudes-cliniques\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/phrg.ca\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Research\",\"item\":\"https:\\\/\\\/phrg.ca\\\/en\\\/recherche\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Clinical trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/phrg.ca\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/phrg.ca\\\/en\\\/\",\"name\":\"PHRG\",\"description\":\"Pulmonary Hypertension Research Group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/phrg.ca\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clinical trials - PHRG","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/phrg.ca\/en\/recherche\/etudes-cliniques\/","og_locale":"en_US","og_type":"article","og_title":"Clinical trials - PHRG","og_description":"[vc_row][vc_column css=&#8221;.vc_custom_1543924365737{padding-right: 25px !important;padding-left: 25px !important;}&#8221;][vc_column_text]Clinical trials constitute the last stage of research, before the marketing of new therapeutic molecules. A rigorous selection process is carried out to choose a [&hellip;]","og_url":"https:\/\/phrg.ca\/en\/recherche\/etudes-cliniques\/","og_site_name":"PHRG","article_modified_time":"2020-10-31T16:04:38+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/phrg.ca\/en\/recherche\/etudes-cliniques\/","url":"https:\/\/phrg.ca\/en\/recherche\/etudes-cliniques\/","name":"Clinical trials - PHRG","isPartOf":{"@id":"https:\/\/phrg.ca\/en\/#website"},"datePublished":"2020-06-22T13:14:12+00:00","dateModified":"2020-10-31T16:04:38+00:00","breadcrumb":{"@id":"https:\/\/phrg.ca\/en\/recherche\/etudes-cliniques\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/phrg.ca\/en\/recherche\/etudes-cliniques\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/phrg.ca\/en\/recherche\/etudes-cliniques\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/phrg.ca\/en\/"},{"@type":"ListItem","position":2,"name":"The Research","item":"https:\/\/phrg.ca\/en\/recherche\/"},{"@type":"ListItem","position":3,"name":"Clinical trials"}]},{"@type":"WebSite","@id":"https:\/\/phrg.ca\/en\/#website","url":"https:\/\/phrg.ca\/en\/","name":"PHRG","description":"Pulmonary Hypertension Research Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/phrg.ca\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/phrg.ca\/en\/wp-json\/wp\/v2\/pages\/16403","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/phrg.ca\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/phrg.ca\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/phrg.ca\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/phrg.ca\/en\/wp-json\/wp\/v2\/comments?post=16403"}],"version-history":[{"count":5,"href":"https:\/\/phrg.ca\/en\/wp-json\/wp\/v2\/pages\/16403\/revisions"}],"predecessor-version":[{"id":16412,"href":"https:\/\/phrg.ca\/en\/wp-json\/wp\/v2\/pages\/16403\/revisions\/16412"}],"up":[{"embeddable":true,"href":"https:\/\/phrg.ca\/en\/wp-json\/wp\/v2\/pages\/16368"}],"wp:attachment":[{"href":"https:\/\/phrg.ca\/en\/wp-json\/wp\/v2\/media?parent=16403"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}